Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bio-Rad expands agreement with CST.


Danvers, MA, 6/6/06-Cell Signaling Technologies (CST CST
abbr.
1. Central Standard Time

2. convulsive shock treatment


CST Central Standard Time

Noun 1.
) has partnered with Bio-Rad Laboratories to develop antibodies for kinase activation and protein phosphorylation phosphorylation, chemical process in which a phosphate group is added to an organic molecule. In living cells phosphorylation is associated with respiration, which takes place in the cell's mitochondria, and photosynthesis, which takes place in the chloroplasts.  assays that will be commercialized in Bio-Rad bead-based multiplex assays. "Bio-Plex phosphoprotein phosphoprotein /phos·pho·pro·tein/ (-pro´ten) a conjugated protein in which phosphoric acid is esterified with a hydroxy amino acid.

phos·pho·pro·tein
n.
 assays built with CST antibody content provide the means for rigorous parallel analysis of signal transduction Signal transduction

The transmission of molecular signals from a cell's exterior to its interior. Molecular signals are transmitted between cells by the secretion of hormones and other chemical factors, which are then picked up by different cells.
 pathways," said CST Director of Business Development Christopher Bunder. Bio-Rad's bead-based assays are used with its Bio-Plex suspension array system, which is based on technology Bio-Rad licenses from Luminex.

Bio-Rad has repeatedly noted strong sales for its bead-based multiplex assays, and this agreement enables it to further grow that business, in 2003, Bio-Rad and CST signed an exclusive supply and co-marketing agreement for assays for the simultaneous measurement of phosphoradiated proteins in parallel signaling pathways.
COPYRIGHT 2006 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Executive Briefing: News Trends & Market Intelligence for Instrument Executives
Publication:Instrument Business Outlook
Geographic Code:1USA
Date:Jun 15, 2006
Words:125
Previous Article:Sigma-Aldrich files suit for infringement of RNAi patents.
Next Article:Q1 Life Science Index operating profit growth slows.
Topics:



Related Articles
FT-IR heads in new directions.
Companies. (Random Samples).
Applied bio gets injunction against Bio-Rad and grants Cepheid license.
Bio-Rad buys MJ GeneWorks.
First quarter results disappoint.
Bio-Rad and Applera discuss settlement.
Bio-Rad acquires Ciphergen's instrument business.
Bio-Rad acquires Blackhawk BioSystems.
New patent suits address groundbreaking techniques.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles